RLFTF (Relief Therapeutics Holding) Accounts Payable & Accrued Expense : $4.03 Mil (As of Dec. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding Accounts Payable & Accrued Expense?

Relief Therapeutics Holding's quarterly accounts payable & accrued expense declined from Dec. 2023 ($5.97 Mil) to Jun. 2024 ($4.18 Mil) and declined from Jun. 2024 ($4.18 Mil) to Dec. 2024 ($4.03 Mil).

Relief Therapeutics Holding's annual accounts payable & accrued expense declined from Dec. 2022 ($6.32 Mil) to Dec. 2023 ($5.97 Mil) and declined from Dec. 2023 ($5.97 Mil) to Dec. 2024 ($4.03 Mil).

Relief Therapeutics Holding Accounts Payable & Accrued Expense Historical Data

The historical data trend for Relief Therapeutics Holding's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Accounts Payable & Accrued Expense Chart

Relief Therapeutics Holding Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

5.98

7.77

6.32

5.97

4.03

Relief Therapeutics Holding Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															6.32	6.31	5.97	4.18	4.03

Relief Therapeutics Holding Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Relief Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFz:UK 0QKQ:UK RLF:Switzerland

Address

Avenue de Secheron 15, Geneva, CHE, 1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.